This result might reflect the biological behavior of the GNAS gene pathway, which is less aggressive than that of the KRAS gene, and further investigation is needed to evaluate the roles of KRAS and GNAS mutations in IPMN carcinogenesis. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.